Quince Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
QNCX$31.73+8.1%Stored close · as of Oct 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net Loss | $(44,521) | $(44,370) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock based compensation | 3,914 | 3,621 |
| Depreciation and amortization | 103 | 170 |
| Change in the fair value of contingent consideration liabilities | 4,522 | 2,082 |
| Change in fair value of debt, net | 1,318 | 1,252 |
| Change in fair value of warrants | 4,173 | — |
| Non-cash goodwill and intangible asset impairment charge | — | 17,130 |
| Amortization of discount on available-for-sale investments | (826) | (1,858) |
| Changes in operating assets and liabilities, net of acquisitions: | ||
| Prepaid expenses and other current assets | 214 | (2,025) |
| Right of use assets, operating leases and operating lease liabilities | 80 | (170) |
| Other assets | (607) | (292) |
| Accounts payable | 214 | (424) |
| Accrued expenses and other current liabilities | 472 | 532 |
| Net cash used in operating activities | (30,944) | (24,352) |
| Cash flow from investing activities: | ||
| Purchase of investments | (29,496) | (89,562) |
| Proceeds from maturities of investments | 45,000 | 100,727 |
| Purchase of property and equipment | (348) | (124) |
| Net cash provided by investing activities | 15,156 | 11,041 |
| Cash flows from financing activities: | ||
| Payment of contingent consideration | — | (5,000) |
| Proceeds from issuance of common stock, common warrants, and pre-funded warrants pursuant to private placement offering, net of issuance costs | 11,426 | — |
| Proceeds from issuance of common stock upon public offering, net of issuance costs | 4,266 | — |
| Proceeds from issuance of common stock upon exercise of stock options | 183 | 225 |
| Net cash provided by (used in) financing activities | 15,875 | (4,775) |
| Effect of exchange rate changes on cash | 153 | 9 |
| Net increase (decrease) in cash and cash equivalents | 240 | (18,077) |
| Cash and cash equivalents at beginning of period | 6,212 | 20,752 |
| Cash and cash equivalents at end of period | $6,452 | $2,675 |
| Supplemental disclosures of cash flow and non-cash information: | ||
| Interest payment on debt | $(176) | $— |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $— | $232 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.